Acro Biomedical (ACBM) Equity Average (2017 - 2025)
Acro Biomedical (ACBM) has 9 years of Equity Average data on record, last reported at -$409791.5 in Q4 2025.
- For Q4 2025, Equity Average fell 41.19% year-over-year to -$409791.5; the TTM value through Dec 2025 reached -$409791.5, down 41.19%, while the annual FY2025 figure was -$340968.0, 23.54% down from the prior year.
- Equity Average reached -$409791.5 in Q4 2025 per ACBM's latest filing, down from -$375069.5 in the prior quarter.
- Across five years, Equity Average topped out at $657372.5 in Q1 2021 and bottomed at -$409791.5 in Q4 2025.
- Average Equity Average over 5 years is $145140.0, with a median of $212649.8 recorded in 2023.
- Peak YoY movement for Equity Average: decreased 2.12% in 2022, then plummeted 661.67% in 2024.
- A 5-year view of Equity Average shows it stood at $605962.5 in 2021, then decreased by 19.26% to $489267.0 in 2022, then plummeted by 150.75% to -$248313.5 in 2023, then fell by 16.88% to -$290238.0 in 2024, then crashed by 41.19% to -$409791.5 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were -$409791.5 in Q4 2025, -$375069.5 in Q3 2025, and -$310713.0 in Q2 2025.